Reema Singh

Delhi, DL 110085, India

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications

"Assessing Long-Term Health-Related Quality of Life in Children with β-Thalassemia Major Following Hematopoietic Stem Cell Transplantation" - A Cross-Sectional Comparative Study.

"Assessing Long-Term Health-Related Quality of Life in Children with β-Thalassemia Major Following Hematopoietic Stem Cell Transplantation" - A Cross-Sectional Comparative Study.

Journal: Hemoglobin
Published: April 07, 2026

Matched Unrelated Donor (MUD) Transplants Show Promising Outcomes in Thalassemia Patients Aged ≤ 12 Years.

Matched Unrelated Donor (MUD) Transplants Show Promising Outcomes in Thalassemia Patients Aged ≤ 12 Years.

Journal: Hemoglobin
Published: March 03, 2026

Response-adapted dasatinib de-escalation strategy compared to upfront Low-dose dasatinib: A prospective cohort study.

Response-adapted dasatinib de-escalation strategy compared to upfront Low-dose dasatinib: A prospective cohort study.

Journal: Leukemia research
Published: December 19, 2025

Is it Necessary to Achieve a Very Good Partial Response Prior to Transplant? Comparison of Outcomes in Pre-Transplant Partial Response Versus Very Good Partial Response or Deeper.

Is it Necessary to Achieve a Very Good Partial Response Prior to Transplant? Comparison of Outcomes in Pre-Transplant Partial Response Versus Very Good Partial Response or Deeper.

Journal: Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion
Published: April 15, 2025

Evaluating Health-Related Quality of Life in Thalassemia: Low-Dose Thalidomide vs. Standard Care-Insights from a Comparative Study.

Evaluating Health-Related Quality of Life in Thalassemia: Low-Dose Thalidomide vs. Standard Care-Insights from a Comparative Study.

Journal: Hemoglobin
Published: March 04, 2025

Allogeneic transplantation for CML blast phase: Learnings over last decade from a single centre in North India.

Allogeneic transplantation for CML blast phase: Learnings over last decade from a single centre in North India.

Journal: Annals of hematology
Published: January 21, 2025

ATG-Thymoglobulin Versus ATG-Fresenius for Conditioning in Thalassemia Patients Who Underwent Allogenic Stem Cell Transplantation from Matched-Sibling Donor: A Tertiary Cancer Care Center Short-Term Experience.

ATG-Thymoglobulin Versus ATG-Fresenius for Conditioning in Thalassemia Patients Who Underwent Allogenic Stem Cell Transplantation from Matched-Sibling Donor: A Tertiary Cancer Care Center Short-Term Experience.

Journal: Hemoglobin
Published: September 05, 2024

Real World Outcome of High-Risk Multiple Myeloma: An Indian Tertiary Care Centre Experience.

Real World Outcome of High-Risk Multiple Myeloma: An Indian Tertiary Care Centre Experience.

Journal: Clinical lymphoma, myeloma & leukemia
Published: June 17, 2024

Real world outcome of B ALL with t (1; 19) (q23; p13)/TCF3::PBX1 in adolescents and adults treated with intensive regimes.

Real world outcome of B ALL with t (1; 19) (q23; p13)/TCF3::PBX1 in adolescents and adults treated with intensive regimes.

Journal: Leukemia research
Published: November 09, 2023

Low fixed dose pembrolizumab with gemcitabine, vinorelbine, liposomal doxorubicin (Pembro100 -GVD) as an effective salvage regimen in relapsed refractory classical hodgkin's lymphoma and primary mediastinal B cell lymphoma.

Low fixed dose pembrolizumab with gemcitabine, vinorelbine, liposomal doxorubicin (Pembro100 -GVD) as an effective salvage regimen in relapsed refractory classical hodgkin's lymphoma and primary mediastinal B cell lymphoma.

Journal: Annals of hematology
Published: August 18, 2023

FLAG based v/s Standard 3 + 7 induction therapy in treatment naïve Acute Myeloid Leukemia: Time to think "beyond anthracyclines".

FLAG based v/s Standard 3 + 7 induction therapy in treatment naïve Acute Myeloid Leukemia: Time to think "beyond anthracyclines".

Journal: Leukemia research
Published: April 17, 2023

End of induction MRD assessment based early treatment intensification with novel agents in ETP-ALL- may be the way forward.

End of induction MRD assessment based early treatment intensification with novel agents in ETP-ALL- may be the way forward.

Journal: Blood research
Published: December 18, 2022
Showing 1-12 of 26

Last Updated: 09/26/2026